AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Managing the procurement and delivery of travel and accommodation agency services for its clients.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits) ...